Abstract | PURPOSE: To analyze the safety and efficacy of sustained-release intravitreal dexamethasone implant (Ozurdex) in management of TB-associated multifocal serpiginoid choroiditis (MSC). METHODS: Retrospective review of TB-associated MSC patients, treated with anti-TB therapy (ATT) and adjunctive intravitreal Ozurdex. RESULTS: Nine eyes of six patients were included. Four patients required Ozurdex implant for progressive or new lesions following ATT and two for additional systemic contraindications to corticosteroids - hyperglycemia and uncontrolled hypertension, respectively. The mean time to resolution was 9.17 ± 7.71 weeks. The mean follow-up post-injection was 13.11 ± 6.05 months (median 12 months [range 6-24.5 months]). Only one of nine eyes developed recurrent MSC lesions and this was attributed to possible autoimmune etiology. Two eyes (22.2%) developed steroid-induced glaucoma - one required implant removal. CONCLUSIONS:
|
Authors | Lubhani Jain, Krushna Gopal Panda, Soumyava Basu |
Journal | Ocular immunology and inflammation
(Ocul Immunol Inflamm)
Vol. 26
Issue 6
Pg. 877-883
( 2018)
ISSN: 1744-5078 [Electronic] England |
PMID | 29020496
(Publication Type: Journal Article)
|
Chemical References |
- Delayed-Action Preparations
- Drug Implants
- Glucocorticoids
- Dexamethasone
|
Topics |
- Adult
- Choroiditis
(diagnosis, drug therapy, etiology)
- Delayed-Action Preparations
- Dexamethasone
(administration & dosage)
- Drug Implants
- Female
- Fluorescein Angiography
- Follow-Up Studies
- Fundus Oculi
- Glucocorticoids
(administration & dosage)
- Humans
- Intravitreal Injections
- Male
- Microscopy, Acoustic
- Middle Aged
- Multifocal Choroiditis
- Ophthalmoscopy
- Retrospective Studies
- Tomography, Optical Coherence
- Treatment Outcome
- Tuberculosis, Ocular
(complications)
- Young Adult
|